FX 002Alternative Names: FX002
Latest Information Update: 06 Sep 2015
At a glance
- Originator Unknown
- Developer Flexion Therapeutics
- Class Anti-inflammatories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 05 Feb 2010 Phase-II clinical trials in Autoimmune disorders in USA (unspecified route)